Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery

Pignon, 2009, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, 92, 4, 10.1016/j.radonc.2009.04.014 Cooper, 2012, Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck, Int J Radiat Oncol Biol Phys, 84, 1198, 10.1016/j.ijrobp.2012.05.008 Priante, 2011, Second primary tumors in patients with head and neck cancer, Curr Oncol Rep, 13, 132, 10.1007/s11912-010-0147-7 Leeman, 2017, Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques, JAMA Oncol, 3, 1487, 10.1001/jamaoncol.2017.0973 Ward, 2018, Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT Era: a multi-institution cohort study by the MIRI collaborative, Int J Radiat Oncol Biol Phys, 100, 586, 10.1016/j.ijrobp.2017.06.012 Haque, 2019, High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma, Oral Oncol, 88, 9, 10.1016/j.oraloncology.2018.11.010 Janot, 2008, Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma, J Clin Oncol, 26, 5518, 10.1200/JCO.2007.15.0102 Carlino, 2021, Immune checkpoint inhibitors in melanoma, Lancet, 398, 1002, 10.1016/S0140-6736(21)01206-X Carlisle, 2020, An update on the immune landscape in lung and head and neck cancers, CA Cancer J Clin, 70, 505, 10.3322/caac.21630 Mody, 2021, Head and neck cancer, Lancet, 398, 2289, 10.1016/S0140-6736(21)01550-6 Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Comprehensive Cancer Network: JNCCN. 2020;18:873-98. Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Cohen, 2019, Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, Lancet, 393, 156, 10.1016/S0140-6736(18)31999-8 Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study, Lancet, 394, 1915, 10.1016/S0140-6736(19)32591-7 Wang, 2021, Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02), J Clin Oncol, 39, 704, 10.1200/JCO.20.02712 Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, et al. Safety, Efficacy, and Biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clin Cancer Res. 2020;26:4250-9. Wang, 2019, Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432, Ann Oncol, 30, 1479, 10.1093/annonc/mdz197 Ueno, 2013, Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study, J Clin Oncol, 31, 1640, 10.1200/JCO.2012.43.3680 Nishimura, 2000, Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells, Cancer Lett, 159, 1, 10.1016/S0304-3835(00)00495-X Tahara, 2015, Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706), Cancer Sci, 106, 726, 10.1111/cas.12657 Ji, 2021, Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial, JAMA Oncol, 10.1001/jamaoncol.2021.2705 Nguyen, 2023, S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor, Cancer Sci, 114, 384, 10.1111/cas.15620 Xu, 2022, Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study, J Cancer Res Clin Oncol Jing, 2022, Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study, Cancer Immunol, Immunother: CII, 71, 2597, 10.1007/s00262-022-03174-9 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242-50. Fu, 2021, Landscape of hyper-progression related gene alterations among Chinese population and their impact on patients’ survival after immunotherapy, J Clin Oncol, 39, e14518, 10.1200/JCO.2021.39.15_suppl.e14518 Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, et al. Genetic Aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019;25:6511-23. Nilsen, 2017, Potential for low-value palliative care of patients with recurrent head and neck cancer, Lancet Oncol, 18, e284, 10.1016/S1470-2045(17)30260-7 Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022;28:468-78. Leddon, 2021, Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: a single-arm phase II multi-institutional study, J Clin Oncol, 39, 6031, 10.1200/JCO.2021.39.15_suppl.6031 Wieland, 2021, Defining HPV-specific B cell responses in patients with head and neck cancer, Nature, 597, 274, 10.1038/s41586-020-2931-3 Helmink, 2020, B cells and tertiary lymphoid structures promote immunotherapy response, Nature, 577, 549, 10.1038/s41586-019-1922-8 Cui, 2021, Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses, Cell, 184, e13